You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
皓元醫藥(688131.SH):擬以不超4.2億元收購藥源藥物100%股權 3月7日復牌
格隆匯 03-04 18:47

格隆匯3月4日丨皓元醫藥(688131.SH)公佈,公司擬向WANG YUAN(王元)、上海源盟、啟東源力、寧波九勝發行股份及支付現金購買其持有的藥源藥物100%股權。

次交易標的資產的交易價格尚未最終確定,預計不超過人民幣4.2億元,標的資產的最終交易價格將以具有證券、期貨相關業務資格的資產評估機構出具的評估結果為依據,由交易各方協商確定,並在此基礎上確定各交易對方具體獲得上市公司支付的股份數量、對應金額及現金對價金額。

公司擬向控股股東安戌信息發行股份募集配套資金,募集配套資金總額不超過5000萬元,募集配套資金總額不超過此次擬以發行股份方式購買資產的交易價格的100%。此次募集配套資金用於支付此次重組相關費用、新建項目投資以及補充流動資金,其中用於補充上市公司和標的公司流動資金的比例不超過募集配套資金總額的50%。

根據相關規定,經公司向上海證券交易所申請,公司股票將於2022年3月7日開市起復牌。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account